NASDAQ:ZEAL - Zealand Pharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$16.04 -0.14 (-0.87 %)
(As of 05/22/2018 06:41 AM ET)
Previous Close$16.18
Today's Range$15.9350 - $16.31
52-Week Range$12.45 - $20.37
Volume4,022 shs
Average Volume10,656 shs
Market Capitalization$497.56 million
P/E Ratio-10.84
Dividend YieldN/A
BetaN/A

About Zealand Pharma (NASDAQ:ZEAL)

Zealand Pharma logoZealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. The company's product pipeline includes glepaglutide, a long acting GLP-2 analog for the treatment of short bowel syndrome, which has completed Phase 2 clinical trials; and dasiglucagon, a proprietary glucagon analog for various indications comprising as a dual-hormone artificial pancreas for diabetes treatment, rescue treatment for severe hypoglycemia, and congenital hyperinsulinism. The company has collaboration agreements with Sanofi-Aventis Deutschland GmbH and Boehringer Ingelheim GmbH. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.

Receive ZEAL News and Ratings via Email

Sign-up to receive the latest news and ratings for ZEAL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ZEAL
CUSIPN/A
Phone45-8877-3600

Debt

Debt-to-Equity RatioN/A
Current Ratio11.19
Quick Ratio11.19

Price-To-Earnings

Trailing P/E Ratio-10.84
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$21.23 million
Price / Sales23.23
Cash FlowN/A
Price / CashN/A
Book Value$2.61 per share
Price / Book6.15

Profitability

EPS (Most Recent Fiscal Year)($1.48)
Net Income$-41,350,000.00
Net Margins-461.34%
Return on Equity-75.67%
Return on Assets-52.78%

Miscellaneous

Employees118
Outstanding Shares30,750,000

Zealand Pharma (NASDAQ:ZEAL) Frequently Asked Questions

What is Zealand Pharma's stock symbol?

Zealand Pharma trades on the NASDAQ under the ticker symbol "ZEAL."

How were Zealand Pharma's earnings last quarter?

Zealand Pharma (NASDAQ:ZEAL) posted its quarterly earnings data on Wednesday, March, 7th. The company reported ($0.58) earnings per share (EPS) for the quarter. The company had revenue of $1.78 million for the quarter. Zealand Pharma had a negative return on equity of 75.67% and a negative net margin of 461.34%. View Zealand Pharma's Earnings History.

What price target have analysts set for ZEAL?

4 brokerages have issued 12 month target prices for Zealand Pharma's stock. Their forecasts range from $26.00 to $28.00. On average, they anticipate Zealand Pharma's stock price to reach $27.3333 in the next year. View Analyst Ratings for Zealand Pharma.

What are Wall Street analysts saying about Zealand Pharma stock?

Here are some recent quotes from research analysts about Zealand Pharma stock:
  • 1. According to Zacks Investment Research, "Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. Zealand Pharma A/S is based in Copenhagen, Denmark. " (3/15/2018)
  • 2. Needham & Company LLC analysts commented, "We recently hosted several meetings with investors and Zealand CEO Britt Jensen. Timelines appear intact for several events over the next 3-4 months, including results from a trial in healthy volunteers evaluating feasibility of once-weekly glepaglutide, presentation of Phase 2 glepaglutide data in Short Bowel Syndrome, initiation of a second Phase 3 dasiglucagon trial for Acute Hypoglycemia, and possibly initiation of a Phase 2/3 trial of dasiglucagon in a single-chamber pump format in Congenital Hyperinsulinism (CHI). Collectively, investors were interested in both glepaglutide and dasiglucagon programs, but individually, were more focused on one or the other. Reiterate BUY. We have not included pump applications of dasiglucagon in our valuation. Progress in the form of a deal with a pump maker and Phase 2/3 trial initiation in CHI would represent an important step forward for the company." (10/16/2017)

Who are some of Zealand Pharma's key competitors?

Who are Zealand Pharma's key executives?

Zealand Pharma's management team includes the folowing people:
  • Ms. Britt Meelby Jensen, Chief Exec. Officer and Pres (Age 45)
  • Mr. Mats Peter Blom MBA, Exec. VP & CFO (Age 53)
  • Ms. Hanne Heidenheim Bak, Sr. Project Director, R&D Operations Mang. and Director (Age 65)
  • Mr. Ivan Møller, Sr. VP of Technical Devel. & Operations
  • Dr. Andrew Parker, Exec. VP & Chief Science Officer (Age 53)

When did Zealand Pharma IPO?

(ZEAL) raised $75 million in an initial public offering on Wednesday, August 9th 2017. The company issued 3,900,000 shares at $19.30 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

Has Zealand Pharma been receiving favorable news coverage?

Media coverage about ZEAL stock has trended somewhat positive this week, Accern Sentiment reports. Accern identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Zealand Pharma earned a media sentiment score of 0.14 on Accern's scale. They also assigned news articles about the company an impact score of 47.81 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are Zealand Pharma's major shareholders?

Zealand Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Farallon Capital Management LLC (2.81%), Millennium Management LLC (0.56%) and Jane Street Group LLC (0.04%). View Institutional Ownership Trends for Zealand Pharma.

Which major investors are selling Zealand Pharma stock?

ZEAL stock was sold by a variety of institutional investors in the last quarter, including Jane Street Group LLC. View Insider Buying and Selling for Zealand Pharma.

Which major investors are buying Zealand Pharma stock?

ZEAL stock was bought by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC and Millennium Management LLC. View Insider Buying and Selling for Zealand Pharma.

How do I buy shares of Zealand Pharma?

Shares of ZEAL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zealand Pharma's stock price today?

One share of ZEAL stock can currently be purchased for approximately $16.04.

How big of a company is Zealand Pharma?

Zealand Pharma has a market capitalization of $497.56 million and generates $21.23 million in revenue each year. The company earns $-41,350,000.00 in net income (profit) each year or ($1.48) on an earnings per share basis. Zealand Pharma employs 118 workers across the globe.

How can I contact Zealand Pharma?

Zealand Pharma's mailing address is SMEDELAND 36 GLOSTRUP, COPENHAGEN G7, 2600. The company can be reached via phone at 45-8877-3600 or via email at [email protected]


MarketBeat Community Rating for Zealand Pharma (ZEAL)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  81 (Vote Outperform)
Underperform Votes:  86 (Vote Underperform)
Total Votes:  167
MarketBeat's community ratings are surveys of what our community members think about Zealand Pharma and other stocks. Vote "Outperform" if you believe ZEAL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZEAL will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Zealand Pharma (NASDAQ:ZEAL) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Zealand Pharma in the last 12 months. Their average twelve-month price target is $27.3333, suggesting that the stock has a possible upside of 70.41%. The high price target for ZEAL is $28.00 and the low price target for ZEAL is $26.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $27.3333$27.3333$27.3333$27.3333
Price Target Upside: 70.41% upside45.08% upside45.08% upside45.08% upside

Zealand Pharma (NASDAQ:ZEAL) Consensus Price Target History

Price Target History for Zealand Pharma (NASDAQ:ZEAL)

Zealand Pharma (NASDAQ:ZEAL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/16/2017Needham & Company LLCReiterated RatingBuy$26.00N/AView Rating Details
9/27/2017Goldman SachsInitiated CoverageBuy ➝ BuyHighView Rating Details
9/5/2017Morgan StanleyInitiated CoverageOverweight ➝ Overweight$28.00HighView Rating Details
9/5/2017GuggenheimInitiated CoverageBuy ➝ Buy$28.00HighView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Zealand Pharma (NASDAQ:ZEAL) Earnings History and Estimates Chart

Earnings by Quarter for Zealand Pharma (NASDAQ:ZEAL)

Zealand Pharma (NASDAQ ZEAL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2018Q4 2017($0.58)$1.78 millionViewN/AView Earnings Details
11/8/2017Q3 2017($0.36)($0.23)$6.33 millionViewN/AView Earnings Details
8/14/2017Q2 2017($0.54)$1.60 millionViewN/AView Earnings Details
5/17/2017Q1 2017($0.15)$11.12 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Zealand Pharma (NASDAQ:ZEAL) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Zealand Pharma (NASDAQ ZEAL) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 10.93%
Insider Trading History for Zealand Pharma (NASDAQ:ZEAL)
Institutional Ownership by Quarter for Zealand Pharma (NASDAQ:ZEAL)

Zealand Pharma (NASDAQ ZEAL) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Zealand Pharma (NASDAQ ZEAL) News Headlines

Source:
DateHeadline
Zealand Pharma A/S 2018 Q1 - Results - Earnings Call SlidesZealand Pharma A/S 2018 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 17 at 5:08 PM
Zealand Pharma - Interim report for the first quarter of 2018Zealand Pharma - Interim report for the first quarter of 2018
finance.yahoo.com - May 16 at 9:27 AM
Zealand Pharma (ZEAL) to Release Earnings on WednesdayZealand Pharma (ZEAL) to Release Earnings on Wednesday
www.americanbankingnews.com - May 15 at 11:39 AM
Innovus Pharmaceuticals (INNV) CEO Bassam Damaj on Q1 2018 Results - Earnings Call TranscriptInnovus Pharmaceuticals' (INNV) CEO Bassam Damaj on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 15 at 9:44 AM
Zealand hosts conference call on May 16 at 4 pm CET/10 am EDT to present first quarter results 2018Zealand hosts conference call on May 16 at 4 pm CET/10 am EDT to present first quarter results 2018
finance.yahoo.com - May 14 at 9:57 AM
ValuEngine Upgrades Zealand Pharma (ZEAL) to HoldValuEngine Upgrades Zealand Pharma (ZEAL) to Hold
www.americanbankingnews.com - May 2 at 1:15 PM
Zealand Pharma to attend Deutsche Bank Securities 43rd Annual Health Care Conference, in Boston on May 8, 2018Zealand Pharma to attend Deutsche Bank Securities 43rd Annual Health Care Conference, in Boston on May 8, 2018
finance.yahoo.com - May 2 at 9:11 AM
Zealand Pharma (ZEAL) Given Average Rating of "Buy" by BrokeragesZealand Pharma (ZEAL) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 2 at 3:34 AM
Blog Exposure - Zealand’s End-of-Phase-2 Meeting with FDA Confirmed the Path Forward for Phase-3 Program of Glepaglutide for Short Bowel SyndromeBlog Exposure - Zealand’s End-of-Phase-2 Meeting with FDA Confirmed the Path Forward for Phase-3 Program of Glepaglutide for Short Bowel Syndrome
finance.yahoo.com - April 30 at 9:24 AM
Zealand to receive $1.8M from Sanofis Q1 sales of Soliqua and LyxumiaZealand to receive $1.8M from Sanofi's Q1 sales of Soliqua and Lyxumia
seekingalpha.com - April 27 at 9:45 AM
Zealand announces net sales of Soliqua® 100/33 and Lyxumia®/Adlyxin® for the first quarter of 2018Zealand announces net sales of Soliqua® 100/33 and Lyxumia®/Adlyxin® for the first quarter of 2018
feeds.benzinga.com - April 27 at 2:00 AM
Zealand announces successful End-of-Phase 2 meeting with FDA on glepaglutide for short bowel syndromeZealand announces successful End-of-Phase 2 meeting with FDA on glepaglutide for short bowel syndrome
feeds.benzinga.com - April 26 at 2:07 AM
Zealand Pharma (ZEAL) and Its Rivals Head-To-Head AnalysisZealand Pharma (ZEAL) and Its Rivals Head-To-Head Analysis
www.americanbankingnews.com - April 25 at 3:20 PM
Sanderss proposed opioid legislation is too focused on the pastSanders's proposed opioid legislation is too focused on the past
www.msn.com - April 19 at 4:49 PM
Sanders unveils bill targeting drug companies over opioid crisisSanders unveils bill targeting drug companies over opioid crisis
www.msn.com - April 19 at 4:49 PM
Analysts Expect Zealand Pharma (ZEAL) to Announce ($0.39) EPSAnalysts Expect Zealand Pharma (ZEAL) to Announce ($0.39) EPS
www.americanbankingnews.com - April 19 at 11:15 AM
Zealand Pharma will attend the Kempen Life Science Conference on April 18, 2018 in AmsterdamZealand Pharma will attend the Kempen Life Science Conference on April 18, 2018 in Amsterdam
feeds.benzinga.com - April 12 at 3:14 AM
BRIEF-Zealand And Roche Diabetes Care Enter Phase 3 Study Collaboration For Treatment Of Congenital Hyperinsulinism With DasiglucagonBRIEF-Zealand And Roche Diabetes Care Enter Phase 3 Study Collaboration For Treatment Of Congenital Hyperinsulinism With Dasiglucagon
www.reuters.com - April 11 at 9:51 AM
Zealand, Roche Collaborate On Phase 3 Trials On Congenital HyperinsulinismZealand, Roche Collaborate On Phase 3 Trials On Congenital Hyperinsulinism
www.nasdaq.com - April 11 at 9:51 AM
Zealand teams up with Roche in late-stage studies of hyperinsulinism candidate dasiglucagonZealand teams up with Roche in late-stage studies of hyperinsulinism candidate dasiglucagon
seekingalpha.com - April 11 at 9:51 AM
Zealand and Roche Diabetes Care enter Phase 3 study collaboration for treatment of congenital hyperinsulinism with dasiglucagonZealand and Roche Diabetes Care enter Phase 3 study collaboration for treatment of congenital hyperinsulinism with dasiglucagon
finance.yahoo.com - April 11 at 9:51 AM
Election of employee representative to Zealands Board of DirectorsElection of employee representative to Zealand's Board of Directors
finance.yahoo.com - April 10 at 9:38 AM
Zealand Pharma (ZEAL) Expected to Post Earnings of -$0.39 Per ShareZealand Pharma (ZEAL) Expected to Post Earnings of -$0.39 Per Share
www.americanbankingnews.com - April 9 at 5:24 PM
Zealand Pharma (ZEAL) Now Covered by GuggenheimZealand Pharma (ZEAL) Now Covered by Guggenheim
www.americanbankingnews.com - April 9 at 12:43 PM
Morgan Stanley Begins Coverage on Zealand Pharma (ZEAL)Morgan Stanley Begins Coverage on Zealand Pharma (ZEAL)
www.americanbankingnews.com - April 9 at 12:10 PM
Zacks: Zealand Pharma (ZEAL) Given Consensus Recommendation of "Buy" by BrokeragesZacks: Zealand Pharma (ZEAL) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 4 at 11:38 AM
What Should You Know About Zealand Pharma A/S’s (CPH:ZEAL) Growth?What Should You Know About Zealand Pharma A/S’s (CPH:ZEAL) Growth?
finance.yahoo.com - March 28 at 9:29 AM
Zealand Pharma convenes its Annual General Meeting 2018Zealand Pharma convenes its Annual General Meeting 2018
finance.yahoo.com - March 22 at 9:29 AM
Zealand Pharma to present at the Needham Healthcare Conference, March 27, 2018 in New YorkZealand Pharma to present at the Needham Healthcare Conference, March 27, 2018 in New York
finance.yahoo.com - March 22 at 9:29 AM
Zacks: Zealand Pharma A/S - American Depositary Shares (ZEAL) Receives Consensus Rating of "Buy" from BrokeragesZacks: Zealand Pharma A/S - American Depositary Shares (ZEAL) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 20 at 10:06 AM
Zealand Pharmas first Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia successfully meets its primary objectiveZealand Pharma's first Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia successfully meets its primary objective
finance.yahoo.com - March 20 at 9:27 AM
Analysts Anticipate Zealand Pharma A/S - American Depositary Shares (ZEAL) to Announce ($0.49) EPSAnalysts Anticipate Zealand Pharma A/S - American Depositary Shares (ZEAL) to Announce ($0.49) EPS
www.americanbankingnews.com - March 15 at 4:01 PM
Zealand Pharma A/S - American Depositary Shares (ZEAL) Cut to "Sell" at Zacks Investment ResearchZealand Pharma A/S - American Depositary Shares (ZEAL) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 15 at 12:50 PM
Zacks: Zealand Pharma A/S - American Depositary Shares (ZEAL) Given $27.33 Consensus Target Price by BrokeragesZacks: Zealand Pharma A/S - American Depositary Shares (ZEAL) Given $27.33 Consensus Target Price by Brokerages
www.americanbankingnews.com - March 9 at 6:07 PM
Zealand Pharma 2017 full-year results in line with guidance - considerable progress in the clinical portfolioZealand Pharma 2017 full-year results in line with guidance - considerable progress in the clinical portfolio
finance.yahoo.com - March 7 at 9:22 AM
Zealand Pharma A/S - American Depositary Shares (ZEAL) Expected to Announce Earnings of -$0.49 Per ShareZealand Pharma A/S - American Depositary Shares (ZEAL) Expected to Announce Earnings of -$0.49 Per Share
www.americanbankingnews.com - March 6 at 11:27 AM
AWM Investment Company Inc. Grows Stake in Zealand Pharma A/S - American Depositary Shares (ZEAL)AWM Investment Company Inc. Grows Stake in Zealand Pharma A/S - American Depositary Shares (ZEAL)
www.americanbankingnews.com - March 6 at 4:45 AM
Zealand Pharma to present at the Cowen & Co. Health Care Conference, March 12, 2018 in BostonZealand Pharma to present at the Cowen & Co. Health Care Conference, March 12, 2018 in Boston
finance.yahoo.com - March 5 at 9:24 AM
Ascendis Pharma (ASND) Proposed $150M Public Offering of ADSsAscendis Pharma (ASND) Proposed $150M Public Offering of ADSs
www.streetinsider.com - February 22 at 4:59 PM
Zacks: Analysts Set $27.33 Target Price for Zealand Pharma A/S - American Depositary Shares (ZEAL)Zacks: Analysts Set $27.33 Target Price for Zealand Pharma A/S - American Depositary Shares (ZEAL)
www.americanbankingnews.com - February 22 at 5:10 AM
Zealand Pharma reports completion of the first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemiaZealand Pharma reports completion of the first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia
finance.yahoo.com - February 21 at 9:16 AM
Zealand Pharma and UniQuest collaborate to develop novel drug candidates for gastrointestinal diseasesZealand Pharma and UniQuest collaborate to develop novel drug candidates for gastrointestinal diseases
finance.yahoo.com - February 20 at 8:56 AM
Zealand Pharmas dasiglucagon Phase 2a results at the 11th International Conference on ATTDZealand Pharma's dasiglucagon Phase 2a results at the 11th International Conference on ATTD
finance.yahoo.com - February 15 at 8:36 AM
Sanofi (SNY) Q4 Earnings Lag on Weak Diabetes/Vaccines SalesSanofi (SNY) Q4 Earnings Lag on Weak Diabetes/Vaccines Sales
www.zacks.com - February 9 at 5:02 PM
Zacks: Zealand Pharma A/S - American Depositary Shares (ZEAL) Given Consensus Recommendation of "Buy" by BrokeragesZacks: Zealand Pharma A/S - American Depositary Shares (ZEAL) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 7 at 11:44 PM
 Zealand Pharma A/S - American Depositary Shares (ZEAL) Given $27.33 Average Target Price by Analysts Zealand Pharma A/S - American Depositary Shares (ZEAL) Given $27.33 Average Target Price by Analysts
www.americanbankingnews.com - February 4 at 3:06 PM
-$0.49 EPS Expected for Zealand Pharma A/S - American Depositary Shares (ZEAL) This Quarter-$0.49 EPS Expected for Zealand Pharma A/S - American Depositary Shares (ZEAL) This Quarter
www.americanbankingnews.com - January 31 at 7:10 PM
Zealand Pharma A/S - American Depositary Shares Lock-Up Period To Expire  on February 5th (NASDAQ:ZEAL)Zealand Pharma A/S - American Depositary Shares' Lock-Up Period To Expire on February 5th (NASDAQ:ZEAL)
www.americanbankingnews.com - January 29 at 1:20 AM
Zealand Pharma hosts Capital Market Day: Accelerating the late stage pipelineZealand Pharma hosts Capital Market Day: Accelerating the late stage pipeline
finance.yahoo.com - January 25 at 4:17 PM
New clinical evidence support potential for glepaglutide as a once-weekly drug for short bowel syndrome (SBS)New clinical evidence support potential for glepaglutide as a once-weekly drug for short bowel syndrome (SBS)
finance.yahoo.com - January 23 at 8:06 AM

SEC Filings

Zealand Pharma (NASDAQ:ZEAL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Zealand Pharma (NASDAQ:ZEAL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Zealand Pharma (NASDAQ ZEAL) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.